11 min read
Monthly FDA Guidance and Regulatory News Review - June 2026
This June 2026 regulatory update focuses on advancing innovative drug development through updated guidance on...
As you look to transition your compound into clinical trials, you need the right partner to guide your planning and decision-making. Whether you are preparing your IND/CTA, or you are looking to recruit patients quickly to get your early phase trials running, or just need medical writing or biostatistical support for your programs – Veristat can help.
We provide impactful solutions on both a full-service or functional service basis, including strategic regulatory guidance, clinical program design, and IND/CTA support through to successful regulatory approval.
Veristat team member Philip Ho , Business Development Director, Asia Pacific, will be at the venue— ready to listen to your needs and share Veristat’s expertise
Schedule a meeting by filling out the form on the right. Find out how we can help you advance your next clinical trial or regulatory submission to successful outcomes.

Website: Bio Asia Taiwan
11 min read
Jul 7, 2026 Veristat Blog
This June 2026 regulatory update focuses on advancing innovative drug development through updated guidance on...
2 min read
Jul 2, 2026 Veristat Blog
June 22, 2026
What the FDA's prior knowledge guidance means for natural history evidence and shared datasets
On June 2,...